ARL4C and liver cancer: Downregulation of ARL4C with siRNA and antisense oligonucleotides (ASOs), such as ASO-1316, is investigated in preclinical research for the treatment of lung adenocarcinoma (Kimura et al., 2020), liver cancer (Harada et al., 2019), and colorectal cancer (Fujii et al., 2015).